Nick Seewald, PhD
Nick Seewald, PhD
About
Research
Publications
Talks
People
Teaching
Software
Contact
Light
Dark
Automatic
Ernesto Ulloa Perez
Latest with Nick
[Abstract] Real-world time on treatment (rwTOT) with first-line (1L) enfortumab vedotin and pembrolizumab (EV+P) after U.S. Food and Drug Administration approval for advanced urothelial cancer (aUC)
Cite
×